Technology
Health
Pharmaceutical
EyePoint Pharmaceuticals
$2.449876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.03 (-1.21%) Today
-$0.03 (-1.21%) Today
Why Robinhood?
You can buy or sell EYPT and other stocks, options, ETFs, and crypto commission-free!
About
EyePoint Pharmaceuticals, Inc. Common Stock, also called EyePoint Pharmaceuticals, is a biopharmaceutical company. Read More It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Employees
44
Headquarters
Watertown, Massachusetts
Founded
1987
Market Cap
233.90M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
520.30K
High Today
$2.46
Low Today
$2.33
Open Price
$2.41
Volume
107.64K
52 Week High
$3.94
52 Week Low
$1.05
Collections
Technology
Health
Pharmaceutical
Biopharmaceutical
US
North America
Female CEOs
News
The Motley FoolMar 14
EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript
EYEPOINT PHARMACEUTICALS INC (NASDAQ:EYPT) Q2 2019 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning. My name is Amanda, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharma's Fiscal Period Ended December 31st, 2018 Financial Results Conference Call. There will be a question-and-answer session to follow at the completion of the prepared rema...
MarketBeatMar 3
Stock Price, News, & Analysis for Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for...
Price Paid on Robinhood
23% Higher
Right Now
52 Week Low
$1.05
Average Price Paid
$1.98
52 Week High
$3.94
Earnings
-$0.91
-$0.64
-$0.38
-$0.11
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.14 per share
Actual
-$0.12 per share